In spite of the recent approval of new promising targeted therapies, the clinical outcome of
patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for …

Allogeneic hematopoietic stem cell transplantation (alloSCT) is an important curative
therapy for high-risk hematological malignancies, but the development of severe and/or …

The key immunologic signatures associated with clinical outcomes after posttransplant
cyclophosphamide (PTCy)-based HLA-haploidentical (haplo) and HLA-matched bone …

Anti-PD-1 monoclonal antibodies yield high response rates in patients with
relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually …

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many solid tumors,
with limited progress made in the area of myeloid malignancies. The low mutational burden …

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) was the first successful
therapy for patients with haematological malignancies, predominantly owing to graft-versus …

Background There have been concerns regarding increased peritransplantation
complications, especially severe acute graft‐versus‐host disease (aGVHD), in patients with …

Natural killer/T-cell lymphomas (NKTCL) represent rare and aggressive lymphoid
malignancies. Patients (pts) with relapsed/refractory disease after Asparaginase (ASPA) …

Early studies in allogeneic blood or marrow transplantation (alloBMT) demonstrated that
HLA-mismatching was protective again relapse. However, benefits in relapse reduction …

Immune checkpoint inhibitors (ICIs) are approved in relapsed classic Hodgkin lymphoma
(cHL). The safety and effectiveness of allogeneic blood or marrow transplantation (alloBMT) …